Single CRISPR infusion cuts stubborn LDL cholesterol for a year
A single dose of CTX310, a CRISPR-Cas9 therapy, dropped LDL cholesterol by more than half in patients who did not respond to standard drugs. The effect lasted at least a year.
Cell & Gene Therapy 13 articles
Cell & Gene Therapy is the umbrella for advanced therapeutic approaches that use living cells or genetic material as the intervention. It connects gene transfer, genetically modified cells, engineered immune cells, manufacturing, delivery, clinical development and regulation without treating these modalities as interchangeable. Gene Therapy and CAR-T have narrower categories; this parent is used when a story spans multiple advanced-therapy modalities or addresses shared development and commercialization challenges.
Australian government funds international CAR-T clinical trials for children
A new five million dollar grant from the Australian Government will bring international CAR-T clinical trials for childhood cancer to Australia, reducing the need for families to seek treatment overseas.
BriaCell Therapeutics advances off-the-shelf cancer immunotherapy into late-stage clinical trials
BriaCell Therapeutics is moving forward with off-the-shelf whole cell immunotherapies for late-stage cancers, with pivotal trials underway and new FDA clearance for prostate cancer.
Ireland’s cell therapy sector depends on imports as demand for activation beads rises
Ireland’s cell therapy industry is growing quickly, but nearly all detachable activation beads are imported. Rising GMP-grade demand and new allogeneic therapies are reshaping the market, but supply chain risks persist.
CAR-T therapy transforms relapsed lymphoma into a race for treatment access
CAR-T therapy offers a lifeline for patients with relapsed blood cancers, but the real challenge is getting the treatment before time and logistics run out.
Latus Bio brings on new board leaders as gene therapy trials approach
Latus Bio has named Donald Hayden as chairman and Michael MacLean as independent director, strengthening its board as the company prepares to start clinical trials for gene therapies targeting CLN2 disease and Huntington’s disease.
Bristol Myers Squibb's arlo-cel meets phase II goal in relapsed multiple myeloma
Bristol Myers Squibb reports that its phase II QUINTESSENTIAL trial of arlocabtagene autoleucel met the main goal in adults with relapsed and refractory multiple myeloma.
Early decisions in cell and gene therapy shape patient access for years
Many cell and gene therapies remain out of reach for patients long after FDA approval. The real barriers are built years earlier, in the choices made around manufacturing, trial design, and regulatory strategy.
BioCytics partners with Eremid for single-cell sequencing in cancer cell therapy
BioCytics has brought in Eremid Genomic Services to run advanced single-cell transcriptomic and TCR sequencing on immune cells, aiming to speed up development of its autologous adaptive immune cell therapy for solid tumors.
CAR-T therapy brings remission for Scottish myeloma patient after standard treatments fail
Adam Nicolson became the first person in Scotland to receive CAR-T cell therapy for myeloma after exhausting all other options. Now in remission, his case is driving new research into the therapy’s potential for autoimmune diseases.
Mayo Clinic scientists find new way to expose hidden thyroid tumors to CAR-T therapy
Mayo Clinic researchers have shown that drugs used for advanced thyroid cancer can make aggressive tumors visible again to CAR-T cells, improving tumor control and survival in preclinical studies.
Single CAR-T injection prompts immune reset in multiple sclerosis trial
A single in vivo CAR-T injection shows early promise for multiple sclerosis, while new research connects ADHD to digestive issues and looks at how wholegrain diets affect heart risk factors.
Arovella Therapeutics gets FDA clearance to start first human trial of ALA-101 cell therapy
Arovella Therapeutics has received FDA clearance to begin Phase 1 clinical testing of its allogeneic cell therapy ALA-101 targeting CD19-positive blood cancers.